[{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GRT-R910","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genevant Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genevant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera \/ Eli Lilly"},{"orgOrder":0,"company":"AbCellera","sponsor":"Vaccine Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bebtelovimab","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Vaccine Research Center","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera \/ Vaccine Research Center"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Inapplicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ NRC IRAP","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ NRC IRAP"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Private Placement","leadProduct":"LSALT Peptide","moa":"DPEP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Undisclosed"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Ingenew Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hesperidin","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valeo Pharma \/ Ingenew Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Valeo Pharma \/ Ingenew Pharma"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hesperidin","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valeo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valeo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Altum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Altum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Altum Pharmaceuticals"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FSD Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Health Canada","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"QBKPN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Health Canada","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Health Canada"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"QBKPN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ NRC IRAP","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ NRC IRAP"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Lipid Nanoparticle platform is the most clinically validated in the space and it use of its for self-amplifying mRNA (samRNA) vaccine candidate, GRT-R910, against COVID-19 in its CORAL program.

                          Product Name : GRT-R910

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 10, 2023

                          Lead Product(s) : GRT-R910

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Metablok (LSALT peptide) is a dipeptidase-1 (DPEP-1) inhibitor which has the ability to block the inflammatory response triggered in the lung and liver with lipopolysaccharide induced inflammation and in the kidney with ischemia/reperfusion induced injur...

                          Product Name : MetaBlok

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          April 18, 2023

                          Lead Product(s) : LSALT Peptide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The funding will be used to support the research and development of the LSALT peptide (Metablok) program. LSALT peptide is the Company’s lead drug candidate for treating acute inflammation injury in the lungs, kidneys and liver.

                          Product Name : MetaBlok

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 23, 2023

                          Lead Product(s) : LSALT Peptide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : NRC IRAP

                          Deal Size : $4.0 million

                          Deal Type : Funding

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Bamlanivimab and bebtelovimab were developed from antibodies that were discovered using AbCellera’s pandemic response platform, in partnership with the Vaccine Research Center (VRC) at the National Institutes for Allergy and Infectious Diseases (NIAID)...

                          Product Name : LY-CoV1404

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 02, 2022

                          Lead Product(s) : Bebtelovimab,Etesevimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Vaccine Research Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Photodynamic Antimicrobial Chemotherapy (PACT) using methylene blue is a potential antimicrobial therapy that combines light and a photosensitizing drug, promoting a phototoxic effect on the treated cells increases membrane permeability in Candida albica...

                          Product Name : PACT

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 08, 2022

                          Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Healthcare's Memorial Health University Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : QBKPN, a first-in-class innate immune modulator that enhances lung immunity, the treatment can improve the innate immune dysfunction that is present in the context of aging, inflammatory lung diseases, and lung cancer.

                          Product Name : QBKPN

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          July 20, 2022

                          Lead Product(s) : QBKPN

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Health Canada

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Metablok (LSALT Peptide), is a novel drug candidate and a new arm of the CATCO human trial, targets acute organ inflammation in the lungs, liver, and kidney which is common in several indications, including moderate to severe cases of COVID-19, regardles...

                          Product Name : MetaBlok

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          April 01, 2022

                          Lead Product(s) : LSALT Peptide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Sunnybrook Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA.

                          Product Name : RVX-208

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 17, 2022

                          Lead Product(s) : Apabetalone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Health Canada has issued a No Objection Letter for the Clinical Trial Application – Amendment to the CATCO team as part of its approval process. Dosing of LSALT peptide is expected to begin following final local approval and clinical site preparation.

                          Product Name : MetaBlok

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 14, 2022

                          Lead Product(s) : LSALT Peptide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : LAU-7b (Fenretinide) is a unique oral COVID-19 antiviral candidate with inflammation-controlling properties, with the potential to work on all mutations of COVID-19 and broader use in the hospital or at-home settings.

                          Product Name : LAU-7b

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 15, 2021

                          Lead Product(s) : Fenretinide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank